beta
Trial Radar AI
Clinical Trial NCT02347995 (REPS) for Stroke is active, not recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One trial matched filter criteria
Card View

Resistive Training Combined With Nutritional Therapy After Stroke (REPS)

Active, not recruiting
Clinical Trial NCT02347995 (REPS) is an interventional study for Stroke that is active, not recruiting. It started on August 24, 2015 with plans to enroll 93 participants. Led by VA Office of Research and Development, it is expected to complete by December 31, 2026. The latest data from ClinicalTrials.gov was last updated on January 30, 2025.
Brief Summary
Stroke survivors experience severe muscle wasting during the chronic phase of recovery, with implications for strength, function and general health. Although resistive exercise training effectively combats this problem, it is unknown whether sub-optimal protein intake limits the observed gains in skeletal muscle growth. Skeletal muscle adaptations may occur when resistive training (RT) is combined with nutritional therapy in the form of post- exercise protein consumption. This study would be the first to directly compare RT+protein supplementation to RT+placebo (same calories as protein supplement) in those with chronic hemiparesis caused by stroke, providing evidence-based rationale for combination therapy in the clinical care of this population.
Detailed Description
The VA research team has played a prominent role in documenting the significant skeletal muscle atrophy that accompanies chronic hemiparesis after disabling stroke. Muscle volume is reduced by 24% in paretic vs. non-paretic legs, having significant implications for strength, function, fitness, metabolism and general health. The investigators' previous work establishes progressive, high-intensity resistive training (RT) as an effective rehabilitation strategy for older stroke survivors, producing thigh muscle hypertrophy on both the paretic and non-paretic sides. Protein supplementation can significantly augment gains in muscle mass after RT in healthy populations, but no experiments have yet been conducted in stroke. New preliminary data from the investigators' group indicates that stroke participants consume 20% less protein than the recommended daily amount for older individuals (0.80 vs. 1.0 g/kg/day) suggesting that relative gains in skeletal muscle could be significantly better in the presence of adequate protein intake. New data also indicates that leg muscle mass predicts resting metabolic rate (RMR) in stroke, implying that a combined nutrition and RT therapy aimed at maximizing muscle gains would translate into improved energy balance, a key factor in rehabilitation success. A better understanding of the true potential for aggressive RT interventions to address stroke-related atrophy and related problems for maximum benefit awaits clinical trials directly comparing RT with and without nutritional therapy. The investigators propose to conduct a 12-week randomized placebo controlled clinical trial comparing the effects of RT+ protein supplementation at 1.2 g/kg/day (RT+PRO) vs. RT+isocaloric placebo (RT+PLA) on body composition, hypertrophy, strength, functional mobility and energy expenditure in chronic stroke.
Official Title

Resistive Training Combined With Nutritional Therapy After Stroke

Conditions
Stroke
Publications
Scientific articles and research papers published about this clinical trial:
Other Study IDs
  • REPS
  • N1461-R
  • HP-00062067 (Other Identifier) (Baltimore VAMC)
NCT ID Number
Start Date (Actual)
2015-08-24
Last Update Posted
2025-01-30
Completion Date (Estimated)
2026-12-31
Enrollment (Estimated)
93
Study Type
Interventional
PHASE
N/A
Status
Active, not recruiting
Keywords
Exercise
Protein
Nutrition
Stroke
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
Double
Arms / Interventions
Participant Group/ArmIntervention/Treatment
Placebo ComparatorResistive Training
Participants will drink a placebo beverage after each resistance training session.
Placebo
This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl.This group will drink a placebo beverage after each training session.
ExperimentalResistive Training + Protein
Participants will drink 30 grams of whey protein after each resistance training session.
Protein
This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl. This group will drink a beverage containing protein after each training session.
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Change in thigh muscle area
muscle area in cm2
Measured at baseline and after the 3 month intervention
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Change in muscle strength
strength
Measured at baseline and after the 3 month intervention
Change in functional mobility (6 min walk distance)
6 min walk distance
Measured at baseline and after the 3 month intervention
Change in myostatin messenger RNA (mRNA) level
myostatin mRNA (AU)
Measured at baseline and after the 3 month intervention
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
30 Years
Eligible Sexes
All
  • Stroke > 3 months prior
  • Completion of all regular post-stroke physical therapy
  • Adequate language and neurocognitive function to participate in testing and training and to provide informed consent
  • Able to walk 10 meters without human assistance

  • Regular structured resistive exercise (>2x/week)
  • Alcohol consumption >3oz. liquor, 3 x 4oz. glasses of wine, or 3 x 12oz beers/day, by self report
  • Neurological history of: a) dementia by clinical evaluation, b) severe receptive or global aphasia, which confounds testing and training, operationally defined as unable to follow 2 point commands, c) untreated major depression by clinical interview
  • Medical History: a) recent hospitalization (less than 3 months prior to study entry) for severe medical disease, b) orthopedic or chronic pain condition restricting exercise, c) pulmonary or renal failure, d) active cancer, e) untreated poorly controlled hypertension measured on at least 2 occasions (greater than 190/100) f) untreated and / or poorly controlled diabetes with fasting blood glucose of greater than 170 and HbA1c greater than 10.0, g) medications: oral steroids, h) currently pregnant
  • Cardiac history of: a) unstable angina, b) recent (less than 3 months prior to study entry) myocardial infarction, congestive heart failure (NYHA category II-IV); c) hemodynamically significant valvular dysfunction
  • Any medical condition that, in the opinion of the Investigator, might interfere with the subject's participation in the study, poses any added risk for the subject, or confounds the assessment of the subject
VA Office of Research and Development logoVA Office of Research and Development
Baltimore VA Medical Center logoBaltimore VA Medical Center
No contact data.
1 Study Locations in 1 Countries

Maryland

Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland, 21201, United States